Additional Payments to Acquire Equity Securities, FV-NI, Expected

No definition available.

Name:	bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected
Namespace Prefix:	bhc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Noncash Cumulative Foreign Currency Translation Loss

+ References

No definition available.

+ Details

Name:	bhc_NoncashCumulativeForeignCurrencyTranslationLoss
Namespace Prefix:	bhc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228

+ Details

Name:	us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITION, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details) - USD ($)			3 Months Ended			9 Months Ended	12 Months Ended
	Jul. 26, 2021	Jun. 23, 2021	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021
Business Acquisition [Line Items]
Upfront payment converted into minor equity interest		$ 10,000,000
Expected additional payments			$ 0			$ 0	$ 0
Disposal Group, Held-for-sale, Not Discontinued Operations \| Amoun
Business Acquisition [Line Items]
Impairment of long-lived assets				$ 96,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Amoun
Business Acquisition [Line Items]
Cash proceeds from divestiture	$ 740,000,000
Impairment of long-lived assets			26,000,000				210,000,000
Noncash cumulative foreign currency translation loss							$ 340,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Amoun \| Asset impairments, including loss on assets held for sale
Business Acquisition [Line Items]
Impairment of long-lived assets						$ 88,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Amoun \| Other (income) expense, net
Business Acquisition [Line Items]
Impairment of long-lived assets			$ 26,000,000
Allegro
Business Acquisition [Line Items]
Acquired IPR&D, included in other (income) expense, net					$ 10,000,000